UROV - Urovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.08 (-0.64%)
As of 3:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.58
Bid12.50 x 1000
Ask12.68 x 1100
Day's Range12.00 - 12.75
52 Week Range10.06 - 14.32
Avg. Volume377,400
Market Cap375.314M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com12 days ago

    Andreas Halvorsen Discloses Stake in Urovant Sciences

    Halvorsen's Viking made one of the largest-ever private biotech investments in its parent company

  • The Wall Street Journal26 days ago

    [$$] Gormley's Take: Urovant Sciences IPO Draws Attention to Urology Market

    went public on Thursday in a deal that highlights a large market that has drawn little venture investment until recently. The company, a spinoff of SoftBank-backed Roivant Sciences, is developing a drug to treat an overactive bladder, a condition that affects millions of Americans and is a serious public-health burden, according to a 2016 study published in the journal Current Bladder Dysfunction Reports. In recent years the number of venture rounds completed in urology each year has typically been in the single digits, according to Dow Jones VentureSource.

  • PR Newswire27 days ago

    Urovant Sciences Ltd. Announces Pricing of Initial Public Offering

    BASEL, Switzerland and IRVINE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, ...

  • Benzingalast month

    The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...